Preclinical stem cell therapy in Chagas Disease: Perspectives for future research

Area of Science:

• Cardiology
• Regenerative Medicine
• Immunology

Background:

• Chagas cardiomyopathy presents a significant health burden in Central and Latin America, leading to high morbidity and mortality.
• The disease impairs heart function through autoimmune mechanisms, causing cardiomyocyte loss and disrupted microcirculation.
• Cell therapy approaches for Chagas disease have been explored in preclinical and clinical settings.

Purpose of the Study:

• To elucidate the reasons behind the limited success of cell therapy in clinical trials for Chagas cardiomyopathy.
• To identify critical discrepancies between preclinical models and human patients that affect therapeutic outcomes.
• To guide future research directions for effective stem cell-based treatments.

Main Methods:

• Review and analysis of existing preclinical data and clinical trial outcomes for cell therapy in Chagas disease.
• Comparative assessment of cellular types and disease pathophysiology between animal models and human patients.
• Discussion of specific examples illustrating the overestimation of efficacy in myocardial regeneration studies.

Main Results:

• Significant differences exist in cellular types and disease mechanisms between preclinical models and human Chagas cardiomyopathy.
• Preclinical findings may not accurately reflect the potential benefits of cell therapy in human patients.
• Current approaches may overestimate the efficacy of myocardial regeneration therapies.

Conclusions:

• Bridging the gap between preclinical efficacy and clinical outcomes is crucial for Chagas disease treatment.
• Future research must prioritize understanding safety, cellular interactions, and human-specific disease aspects.
• Optimizing stem cell therapy requires addressing these translational challenges to improve patient outcomes.